In patients with systemic lupus erythematosus, impaired upper limb function and difficulty performing daily activities are linked to various quality-of-life domains.

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

In patients with active systemic lupus erythematosus unresponsive to conventional hydroxychloroquine-based therapy, adding mepacrine shows improved outcomes with few and mild side effects.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

Please provide your email address to receive an email when new articles are posted on . Among targeted small-molecule drugs, deucravacitinib had the best efficacy and safety in SLE. Dose and course of ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...